Munich Reinsurance Co Stock Corp in Munich Takes Position in Hologic, Inc. $HOLX

Munich Reinsurance Co Stock Corp in Munich acquired a new position in shares of Hologic, Inc. (NASDAQ:HOLX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 61,962 shares of the medical equipment provider’s stock, valued at approximately $4,182,000.

Several other institutional investors have also made changes to their positions in the business. The Manufacturers Life Insurance Company raised its position in Hologic by 294.3% in the second quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock worth $718,223,000 after purchasing an additional 8,227,318 shares in the last quarter. Invesco Ltd. boosted its holdings in Hologic by 72.5% during the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock valued at $543,486,000 after purchasing an additional 3,505,828 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Hologic by 1.7% during the second quarter. Geode Capital Management LLC now owns 5,828,325 shares of the medical equipment provider’s stock valued at $378,209,000 after purchasing an additional 97,142 shares in the last quarter. Black Creek Investment Management Inc. grew its stake in shares of Hologic by 26.1% in the 2nd quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock valued at $262,453,000 after purchasing an additional 832,444 shares during the period. Finally, Bank of America Corp DE raised its holdings in shares of Hologic by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 3,090,306 shares of the medical equipment provider’s stock worth $201,364,000 after buying an additional 66,453 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on HOLX shares. Argus downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. BNP Paribas Exane lowered Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price objective for the company. in a research note on Friday, November 21st. Evercore cut Hologic from an “outperform” rating to an “in-line” rating and cut their price objective for the company from $79.00 to $78.00 in a report on Monday, January 5th. Finally, Morgan Stanley upped their target price on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Two investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $78.42.

Hologic Stock Down 0.0%

Shares of HOLX opened at $75.74 on Friday. The company has a market capitalization of $16.91 billion, a P/E ratio of 31.56, a PEG ratio of 2.25 and a beta of 0.73. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. Hologic, Inc. has a one year low of $51.90 and a one year high of $75.75. The business’s 50 day simple moving average is $75.04 and its 200-day simple moving average is $72.41.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the business earned $0.87 earnings per share. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. As a group, sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.